19 September 2018 AMSBIO announce the launch of a new range of circulating tumor DNA (ctDNA) Reference Standards for cancer disease management research.A critical goal in cancer disease management is early detection. When detected early, cancer progression can be arrested using techniques such as targeted therapy, chemotherapy and surgery thereby increasing the chances of survival and a higher quality of life. Liquid biopsy offers the promise of providing a quick, non-invasive and cost-effective alternative to surgical biopsies, allowing tumor analysis through a simple blood sample. Traces of…

17 September 2018 Science Exchange, the leading marketplace for outsourced R&D™, announced today that it has become a Corporate Partner of One Nucleus, the membership organization for life science and healthcare companies. This exclusive partnership will give One Nucleus members immediate access to thousands of CROs, CMOs, academic institutes, core labs and a global community of scientists from the world’s top R&D organizations.Based in Cambridge, England, One Nucleus supports institutions, companies, and individuals in its region by connecting them to a vast network of UK-wide and…

17 September 2018 Cambridge and Ongar, UK, 17th September 2018 / Sciad Newswire / A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal of Medicinal Chemistry. The authors describe the identification of synthetic, macrocyclic, orally bioavailable cyclophilin inhibitors with potent HCV activity. These compounds also provide starting points for drug discovery programmes in several other major diseases…

17 September 2018 Cambridge, UK, September 14 2018: Owlstone Medical Ltd (or the “Company”), a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.   Dr Richards is a serial entrepreneur and business angel with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. His early career spans positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive…

17 September 2018 Cambridge, UK, 17 September 2018: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System. The software works alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows.Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, isolation and clone verification. Its…

13 September 2018     Draft Coverage Supports the Use of InVisionFirst-Lung for Aiding in the Management of Patients with Advanced Non-Small-Cell Lung Cancer   Research Triangle Park, NC and Cambridge, UK, September 13, 2018 -- Inivata, a leader in liquid biopsy, today announces that Palmetto GBA, a Medicare Administrative Contractor that  evaluates diagnostic technology through its laboratory technology assessment group, MolDx, has published a draft local coverage determination (LCD) for the InVisionFirst-Lung test. The draft LCD recommends coverage for InVisionFirst-Lung…

12 September 2018 Michelle Gale joins as Head of Customer Services, Dr Ben Cliff as Vice President of Operations, and Lorraine Bater as Regional Director of the South, UK  Appointments support provision of routine testing, monitoring and specialist analysis services to life sciences, food & consumer services, and industrial and environmental services industries Manchester, UK, 12 September 2018: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has made three senior appointments to its Analytical Services…

Babraham 10 September 2018: The Babraham Research Campus is delighted to announce Taylor Vinters and Silicon Valley Bank as the latest organisations to pledge support for the Babraham Research Campus’ life-science accelerator, Accelerate@Babraham.Designed to support the earliest stages of new life-science ventures, via the provision of easy-access laboratory and office space together with supporting programmes of business, science, finance and entrepreneurial mentoring, Accelerate@Babraham’s inaugural programme starts later this month. Six companies are enrolled on the programme, five of…

The successfully defended patent protects novel compositions of a specific type and group of vaccines, called polysaccharide vaccines. Examples of polysaccharide vaccines are vaccines that are used to protect against Meningitis or Pneumonia. Such products are known to degrade over time, leading to gradual loss of potency. The novel compositions protected by this patent prevent such degradation and enable the development of improved polysaccharide vaccines in more convenient dosage forms that can be used outside the cold chain, thereby increasing the efficiency of immunisation coverage.Arecor’…

$133 Million Deal Adds European Early Development Center of Excellence to Global NetworkSOMERSET, N.J., July 3, 2018 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the U.S. and Europe, the acquisition of…